Drugs / BI 54903 XX
last change Jul 2009 re-read 2 minutes ago

BI 54903 XX

Investigated by
Boehringer Ingelheim

Trials 1 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02221375 Jun → Sep 2008 Boehringer Ingelheim Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02222428 Comparator Apr → Jul 2009 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02220660 Comparator Mar → Jun 2009 Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as BI 54903 XX ClinicalTrials.gov intervention name — accepted as the source's own label NCT02220660
2

NCT02222428

NCT02221375

Route Inhaled “following inhalation of the free dose combination of BI 1744 CL (as aqueous solution for inhalation, AIS) and BI 54903 XX (EIS), respectively” NCT02220660